INBX smart money
Inhibrx Biosciences, INC. (INBX): 6 insider buys, 4 top funds holding it in the public filings.
Insider buys, 12 months$5.5M
Insider buys
| Filed | Who | Role | Amount | Price |
|---|---|---|---|---|
| 2026-09-28 | Lappe Mark | Chief Executive Officer | $999k | $98.87 |
| 2026-09-23 | Kayyem Jon Faiz | Director | $500k | $100.0 |
| 2026-09-17 | Kayyem Jon Faiz | Director | $500k | $100.0 |
| 2026-09-08 | Lappe Mark | Chief Executive Officer | $2.6M | $108.24 |
| 2026-09-08 | Kayyem Jon Faiz | Director | $568k | $113.52 |
| 2026-09-08 | Forsyth Douglas | Director | $287k | $114.65 |
Top 100 funds holding it
| # | Fund | Change | Weight | Value |
|---|---|---|---|---|
| 46 | Sofinnova Investments, INC. | ADD +29% | 1.93% | $39M |
| 74 | First Turn Management, LLC | ADD +4% | 2.28% | $17M |
| 84 | Soleus Capital Management, L.P. | BUY | 0.75% | $21M |
| 96 | Pfm Health Sciences, LP | ADD +4% | 3.42% | $32M |